The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

Metformin, a chemical relative of that compound, has been a top type 2 diabetes treatment in the United States since it was approved in 1994. It’s cheap—less than a dollar per dose—and readily ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

So far, Zepbound has seemed superior, as testing showed treatment helped people with obesity lose up to 21% of their body weight. The comparative figure for Wegovy was 16% in the Phase 3 trials Novo ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...